FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214596719> ?p ?o ?g. }

• W4214596719 endingPage "287" @default.
• W4214596719 startingPage "287" @default.
• W4214596719 abstract "Antibiotic treatment strategies for fracture-related infections (FRI) are often extrapolated from periprosthetic joint infections (PJI), although, in contrast to PJI, detailed analysis of pathogens and their antibiotic resistance is missing. Therefore, this study aimed to investigate antibiotic susceptibility profiles to identify effective empiric antibiotic treatment for early-, delayed-, and late-onset FRI. Patients treated for FRI from 2013 to 2020 were grouped into early (<2 weeks), delayed (3−10 weeks), and late (>10 weeks) onset of infection. Antibiotic susceptibility profiles were examined with respect to broadly used antibiotics and antibiotic combinations. In total, 117 patients (early n = 19, delayed n = 60, late n = 38) were enrolled. In early-onset FRI, 100.0% efficacy would be achieved by meropenem + vancomycin, gentamicin + vancomycin, co-amoxiclav + glycopeptide, ciprofloxacin + glycopeptide and piperacillin/tazobactam + glycopeptide. For patients with delayed FRI, the highest susceptibility was revealed for meropenem + vancomycin, gentamicin + vancomycin and ciprofloxacin + glycopeptide (96.7%). Meropenem + vancomycin was the most effective empiric antimicrobial in patients with late-onset of infection with 92.1% coverage. No subgroup differences in antibiotic sensitivity profiles were observed except for the combination ciprofloxacin + glycopeptide, which was significantly superior in early FRI (F = 3.304, p = 0.04). Across all subgroups meropenem + vancomycin was the most effective empiric treatment in 95.7% of patients with confirmed susceptibility. Meropenem + vancomycin, gentamicin + vancomycin, co-amoxiclav + glycopeptide are the best therapeutic options for FRI, regardless of the onset of infection. To avoid multidrug resistance, established antibiotic combinations such as co-amoxiclav with a glycopeptide seem to be reasonable as a systemic antibiotic therapy, while vancomycin + gentamicin could be implemented in local antibiotic therapy to reduce adverse events during treatment." @default.
• W4214596719 created "2022-03-02" @default.
• W4214596719 creator A5015064679 @default.
• W4214596719 creator A5024432591 @default.
• W4214596719 creator A5035875325 @default.
• W4214596719 creator A5043380675 @default.
• W4214596719 creator A5046991836 @default.
• W4214596719 creator A5050772996 @default.
• W4214596719 creator A5074155735 @default.
• W4214596719 date "2022-02-22" @default.
• W4214596719 modified "2023-10-14" @default.
• W4214596719 title "What Is the Most Effective Empirical Antibiotic Treatment for Early, Delayed, and Late Fracture-Related Infections?" @default.
• W4214596719 cites W1988408370 @default.
• W4214596719 cites W2000445173 @default.
• W4214596719 cites W2043584152 @default.
• W4214596719 cites W2057716016 @default.
• W4214596719 cites W2074508865 @default.
• W4214596719 cites W2095193057 @default.
• W4214596719 cites W2154366164 @default.
• W4214596719 cites W2159359720 @default.
• W4214596719 cites W2180892169 @default.
• W4214596719 cites W2277898411 @default.
• W4214596719 cites W2346119783 @default.
• W4214596719 cites W2519128930 @default.
• W4214596719 cites W2565354201 @default.
• W4214596719 cites W2570797908 @default.
• W4214596719 cites W2593745427 @default.
• W4214596719 cites W2606636476 @default.
• W4214596719 cites W2609779788 @default.
• W4214596719 cites W2620722239 @default.
• W4214596719 cites W2747036772 @default.
• W4214596719 cites W2884151063 @default.
• W4214596719 cites W2889009153 @default.
• W4214596719 cites W2896241835 @default.
• W4214596719 cites W2899841051 @default.
• W4214596719 cites W2951468407 @default.
• W4214596719 cites W2956803844 @default.
• W4214596719 cites W2961603915 @default.
• W4214596719 cites W2962354221 @default.
• W4214596719 cites W2969375211 @default.
• W4214596719 cites W2976048340 @default.
• W4214596719 cites W2982538373 @default.
• W4214596719 cites W2983115252 @default.
• W4214596719 cites W3005889885 @default.
• W4214596719 cites W3037739829 @default.
• W4214596719 cites W3064231995 @default.
• W4214596719 cites W3084311138 @default.
• W4214596719 cites W3160128285 @default.
• W4214596719 cites W3161740531 @default.
• W4214596719 cites W3171667013 @default.
• W4214596719 cites W3183347527 @default.
• W4214596719 cites W3194335071 @default.
• W4214596719 cites W3200569483 @default.
• W4214596719 cites W4200451295 @default.
• W4214596719 doi "https://doi.org/10.3390/antibiotics11030287" @default.
• W4214596719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35326751" @default.
• W4214596719 hasPublicationYear "2022" @default.
• W4214596719 type Work @default.
• W4214596719 citedByCount "11" @default.
• W4214596719 countsByYear W42145967192022 @default.
• W4214596719 countsByYear W42145967192023 @default.
• W4214596719 crossrefType "journal-article" @default.
• W4214596719 hasAuthorship W4214596719A5015064679 @default.
• W4214596719 hasAuthorship W4214596719A5024432591 @default.
• W4214596719 hasAuthorship W4214596719A5035875325 @default.
• W4214596719 hasAuthorship W4214596719A5043380675 @default.
• W4214596719 hasAuthorship W4214596719A5046991836 @default.
• W4214596719 hasAuthorship W4214596719A5050772996 @default.
• W4214596719 hasAuthorship W4214596719A5074155735 @default.
• W4214596719 hasBestOaLocation W42145967191 @default.
• W4214596719 hasConcept C126322002 @default.
• W4214596719 hasConcept C137610392 @default.
• W4214596719 hasConcept C2775832221 @default.
• W4214596719 hasConcept C2776703206 @default.
• W4214596719 hasConcept C2777637488 @default.
• W4214596719 hasConcept C2777858937 @default.
• W4214596719 hasConcept C2778193466 @default.
• W4214596719 hasConcept C2778266534 @default.
• W4214596719 hasConcept C2778512257 @default.
• W4214596719 hasConcept C2778980435 @default.
• W4214596719 hasConcept C2779375183 @default.
• W4214596719 hasConcept C2779390152 @default.
• W4214596719 hasConcept C2779489039 @default.
• W4214596719 hasConcept C2779631663 @default.
• W4214596719 hasConcept C501593827 @default.
• W4214596719 hasConcept C523546767 @default.
• W4214596719 hasConcept C54355233 @default.
• W4214596719 hasConcept C71924100 @default.
• W4214596719 hasConcept C86803240 @default.
• W4214596719 hasConcept C89423630 @default.
• W4214596719 hasConcept C94665300 @default.
• W4214596719 hasConceptScore W4214596719C126322002 @default.
• W4214596719 hasConceptScore W4214596719C137610392 @default.
• W4214596719 hasConceptScore W4214596719C2775832221 @default.
• W4214596719 hasConceptScore W4214596719C2776703206 @default.
• W4214596719 hasConceptScore W4214596719C2777637488 @default.
• W4214596719 hasConceptScore W4214596719C2777858937 @default.
• W4214596719 hasConceptScore W4214596719C2778193466 @default.

• next